{"id":991213,"date":"2026-08-06T08:54:02","date_gmt":"2026-08-06T12:54:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-clinical-updates\/"},"modified":"2026-08-06T08:54:02","modified_gmt":"2026-08-06T12:54:02","slug":"lexicon-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-clinical-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-clinical-updates\/","title":{"rendered":"Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates\u00a0"},"content":{"rendered":"
\n

\n
\n Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027\u00a0<\/em>
\n <\/strong>\n <\/p>\n

\n
\n NDA resubmission activities for ZYNQUISTA<\/em>
\n <\/strong>
\n
\n
\n \u00ae<\/em>
\n <\/strong>
\n <\/sup>
\n
\n in type 1 diabetes nearing completion<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Phase 1 clinical development of LX9851 ongoing by Novo Nordisk <\/em>
\n <\/strong>\n <\/p>\n

\n
\n Conference call and webcast at 8:30 am ET<\/em>
\n <\/strong>\u00a0\u00a0<\/p>\n

THE WOODLANDS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc.<\/a> (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and accomplishments.\u00a0<\/p>\n

\u201cLexicon continued to make strong progress during the second quarter, with the refinement of our strategy and sharpening of our focus beginning to bear fruit across our business,\u201d said Mike Exton, Ph.D., Lexicon\u2019s chief executive officer and director. \u201cAmong all the accomplishments, I\u2019m particularly pleased that we have completed enrollment of our SONATA-HCM study on time, reflecting strong clinical interest for a novel class of medicine to treat HCM. Overall, I could not be more confident in how these opportunities are poised to shape the company over the coming months.\u201d<\/p>\n

\u201cWe remain very focused on disciplined, targeted capital allocation as we continue to advance our clinical programs,\u201d said Scott Coiante, Lexicon\u2019s chief financial officer. \u201cWith early commercial planning now underway for our late-state pipeline, we are committed to maximizing the value of these opportunities to create long-term shareholder value.\u201d<\/p>\n

\n
\n Second Quarter 2026 Business and Pipeline Highlights<\/u>
\n <\/strong>\u00a0<\/p>\n

\n
\n Cardiometabolic<\/em>
\n <\/strong>\n <\/p>\n

\n Sotagliflozin <\/strong>
\n
Sotagliflozin is a unique oral inhibitor of sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2) and has been studied in approximately 20,000 patients across multiple cardiometabolic indications. Sotagliflozin is commercially available in the U.S. for heart failure as INPEFA\u00ae<\/sup>.<\/p>\n

\n Hypertrophic Cardiomyopathy (HCM<\/strong>)<\/p>\n